Perspective Therapeutics, Inc. (NYSE:CATX) Director Acquires $100,003.75 in Stock

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) Director Heidi Henson purchased 25,975 shares of the business's stock in a transaction that occurred on Wednesday, December 4th. The stock was bought at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the acquisition, the director now owns 25,975 shares in the company, valued at approximately $100,003.75. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Perspective Therapeutics Price Performance

NYSE:CATX traded up $0.04 during midday trading on Friday, hitting $3.76. 1,457,037 shares of the stock were exchanged, compared to its average volume of 852,446. The business has a 50-day moving average price of $9.93 and a two-hundred day moving average price of $12.00. Perspective Therapeutics, Inc. has a one year low of $2.28 and a one year high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). The business had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. Equities research analysts anticipate that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CATX shares. Cantor Fitzgerald reissued an "overweight" rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Royal Bank of Canada reduced their target price on shares of Perspective Therapeutics from $25.00 to $16.00 and set an "outperform" rating for the company in a research note on Monday, November 25th. Bank of America lowered shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and dropped their price target for the company from $24.00 to $5.00 in a research note on Monday, November 25th. Truist Financial started coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They set a "buy" rating and a $21.00 price objective for the company. Finally, Oppenheimer cut their target price on Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating on the stock in a research note on Friday, November 22nd. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $15.14.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds have recently made changes to their positions in CATX. nVerses Capital LLC bought a new position in shares of Perspective Therapeutics in the third quarter valued at $57,000. US Bancorp DE increased its stake in Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company's stock worth $88,000 after purchasing an additional 3,866 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Perspective Therapeutics during the 3rd quarter worth about $137,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Perspective Therapeutics in the third quarter worth about $152,000. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Perspective Therapeutics in the third quarter worth about $153,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.